Skip to main content
Log in

Chromium Supplementation Reduces Resting Heart Rate in Patients with Metabolic Syndrome and Impaired Glucose Tolerance

  • Published:
Biological Trace Element Research Aims and scope Submit manuscript

Abstract

Chromium (Cr) is considered as an important mineral, involved in biochemical reactions in human metabolic pathways. Organically bound Cr supplementation has been suggested to improve glycemia especially in patients with type 2 diabetes mellitus, but there are conflicting reports on efficacy. Effect of Cr is not clear in prediabetes status. Seventy patients with metabolic syndrome and impaired glucose tolerance (IGT), who are observed and treated in the Center of Preventive Cardiology of the University Hospital in Pilsen, were included in the prospective, randomized, double-blind, and placebo-controlled clinical study. Effect of Cr-enriched yeast (200 μg of elementary Cr in the morning and 100 μg in the evening) on glucose, lipid metabolism, fat tissue hormones, oxidative stress, and DNA damage markers was analyzed. There were no significant changes in glucose and lipid parameters, oxidative stress, or other laboratory markers. Only resting heart rate was significantly reduced in patients treated by Cr yeast, reflecting reduced sympathetic activity. This could represent an important cardiovascular risk reduction in patients with high cardiometabolic risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Authors/Task Force Members, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes H, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Sousa Uva M, Taskinen M, Tendera M, Tuomilehto J, Valensi P, Zamorano JL (2013) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with EASD. Eur Heart J 34:3035–3087

    Article  Google Scholar 

  2. Cefalu WT, Hu FB (2004) Role of chromium in human health and in diabetes. Diabetes Care 27:2741–2751

    Article  CAS  Google Scholar 

  3. Mahdi GS (1995) Barley as high-chromium food. J Am Diet Assoc 95:7

    Article  Google Scholar 

  4. Institute of Medicine, Food and Nutrition Board (2001) Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. National Academy Press, Washington, DC

    Google Scholar 

  5. Wallach S (1985) Clinical and biochemical aspects of chromium deficiency. J Am Coll Nutr 4:107–120

    Article  CAS  Google Scholar 

  6. Sreekanth R, Pattabhi V, Rajan SS (2008) Molecular basis of chromium insulin interactions. Biochem Biophys Res Commun 369:725–729

    Article  CAS  Google Scholar 

  7. Balk EM, Tatsioni A, Lichtenstein AH et al (2007) Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care 30:2154–2163

    Article  CAS  Google Scholar 

  8. Racek J, Sindberg CD, Moesgaard S et al (2013) Effect of chromium-enriched yeast on fasting plasma glucose, glycated haemoglobin and serum lipid levels in patients with type 2 diabetes mellitus treated with insulin. Biol Trace Elem Res 155(1):1–4

    Article  CAS  Google Scholar 

  9. Alberti KGMM, Eckel R, Grundy S et al (2009) Harmonizing the metabolic syndrome. Circulation 120:1640–1645

    Article  CAS  Google Scholar 

  10. Rosolová H, Mayer O, Šimon J et al (1999) Detection of insulin resistance in Czech population. Cas Lek Ces (in Czech) 137:80–83

    Google Scholar 

  11. Jentzsch AM, Bachmann H, Fürst P, Biesalski HK (1996) Improved anylysis of malondialdehyde in human body fluids. Free Radic Biol Med 20:251–256

    Article  CAS  Google Scholar 

  12. Kalousová M, Škrha J, Zima T (2002) Advanced glycation end-produts and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 51:597–604

    PubMed  Google Scholar 

  13. Levy JC, Matthews DR, Hermans MP (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191–2192

    Article  CAS  Google Scholar 

  14. Dobiášová M (2004) Atherogenic index of plazma [Log triglycerides/HDL-cholesterol]: theoretical and practical implications. Clin Chem 50:113–115

    Google Scholar 

  15. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497

    Article  CAS  Google Scholar 

  16. Reaven GM, Lithell L, Landsberg L (1996) Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. N Engl J Med 334:374–381

    Article  CAS  Google Scholar 

  17. Mancia G, Di Rienzo M, Giannattasio C et al (1998) Early and late sympathetic activation in hypertension. Scand Cardiovasc J 32:9–13

    Article  Google Scholar 

  18. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM (2007) Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49:403–414

    Article  CAS  Google Scholar 

  19. Ashoush S, Abou-Gamrah A, Baumy H et al (2016) Chromium picolinate reduces insulin resistance in polycystic ovary syndrome. Randomized controlled trial J Obstet Gynecol Res 42:279–285

    Article  CAS  Google Scholar 

  20. Wiernsperger N, Rapin J (2010) Trace elements in glucometabolic disorders: an update. Diabetol Metab Syndr 2:70

    Article  CAS  Google Scholar 

  21. Fiorentino TV, Prioletta A, Zuo P, Folli F (2013) Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Des 19(32):5695–5703

    Article  CAS  Google Scholar 

  22. Roberts CK, Sindhu KK (2009) Oxidative stress and metabolic syndrome. Life Sci 84(21–22):705–712

    Article  CAS  Google Scholar 

  23. Jeejeebhoy KN (1999) The role of chromium in nutrition and therapeutics and as a potential toxin. Nutr Rev 57:329–335

    Article  CAS  Google Scholar 

  24. Mclyer DJ, Grizales AM, Brownstein JS et al (2015) Risk of type 2 diabetes is lower in US adults taking chromium containing supplements. J Nutr 145:2675–2682

    Article  Google Scholar 

  25. Gunton JE, Cheung NW, Hitchman R et al (2005) Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance. Diabetes Care 28:712–713

    Article  Google Scholar 

  26. Bailey CH (2014) Improved meta-analytic methods show no effect of chromium supplements on fasting glucose. Biol Trace Elem Res 157:1–8

    Article  CAS  Google Scholar 

  27. Iqbal N, Cardillo S, Volger S et al (2009) Chromium picolinate does not improve key features of metabolic syndrome in obese nondiabetic adults. Metab Syndr Relat Disord 7:143–150

    Article  CAS  Google Scholar 

  28. Vincent JB (2014) Is chromium pharmacologically relevant? Biol Trace Elem Res 28(4):397–405

    Article  CAS  Google Scholar 

  29. Ali A, Ma Y, Reynolds J, Wise JP Sr et al (2011) Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus. Endocr Pract 17(1):16–25

    Article  Google Scholar 

  30. Wang ZW, Cefalu WT (2010) Current concepts about chromium supplementation in type 2 diabetes and insulin resistance. Curr Diab Rep 10:145–151

    Article  Google Scholar 

Download references

Acknowledgements

Christian Sindberg, M.Sc., is an empolyee of Research Department, Pharma Nord ApS, Vejle, Denmark. Pharma Nord, Denmark, provided placebo, Cr tablets, and glucose solutions for oGTT. However, no monies were received from Pharma Nord. Laboratory methods were supported by the Charles University Research Grant (Medical Faculty in Pilsen P-36).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christian Sindberg.

Ethics declarations

The study was approved by the local Ethical Committee of the University Hospital in Pilsen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nussbaumerova, B., Rosolova, H., Krizek, M. et al. Chromium Supplementation Reduces Resting Heart Rate in Patients with Metabolic Syndrome and Impaired Glucose Tolerance. Biol Trace Elem Res 183, 192–199 (2018). https://doi.org/10.1007/s12011-017-1128-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12011-017-1128-6

Keywords

Navigation